Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48(12):1246–1252

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141–149

Article  PubMed  Google Scholar 

Drachman DB (1994) Myasthenia gravis. N Engl J Med 330(25):1797–1810

Article  CAS  PubMed  Google Scholar 

Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52:90–100

Article  CAS  PubMed  Google Scholar 

Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10(11):2235

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGrogan A, Sneddon S, de Vries CS (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 34(3):171–183

Article  PubMed  Google Scholar 

Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17(7):893–902

Article  CAS  PubMed  Google Scholar 

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419–425

Article  PubMed  PubMed Central  Google Scholar 

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114–122

Article  PubMed  PubMed Central  Google Scholar 

Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570–2581

Article  CAS  PubMed  Google Scholar 

Jani-Acsadi A, Lisak RP (2010) Myasthenia gravis. Curr Treat Options Neurol 12(3):231–243

Article  PubMed  Google Scholar 

Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036

Article  CAS  PubMed  Google Scholar 

Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15(3):291–298

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976–986

Article  CAS  PubMed  Google Scholar 

Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270(8):3862–3875

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395–406

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526–536

Article  CAS  PubMed  Google Scholar 

Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383–394

Article  CAS  PubMed  Google Scholar 

Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128(10):4372–4386

Article  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661–e2673

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riley TR, Douglas JS, Wang C, Bowser KM (2023) An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies. Am J Health Syst Pharm 80(11):652–662

Article  PubMed  Google Scholar 

Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, Vidarsson G (2021) IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. J Neurol Sci 430:118074

Article  CAS  PubMed  Google Scholar 

Heo YA (2022) Efgartigimod: first approval. Drugs 82(3):341–348

Article  CAS  PubMed  PubMed Central  Google Scholar 

VYVGART 2021 (efgartigimod alfa-fcab) injection, for intravenous use. US Food and Drug Administration (FDA) approved product information. Revised December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf (Accessed on June 22, 2023).

Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O’Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ (2022) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98(4):e376–e389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lascano AM, Lalive PH (2021) Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev 20(1):102712

Article  CAS  PubMed  Google Scholar